Jane Street’s Aclaris Therapeutics ACRS Stock Holding History

Jane Street’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-21,700	Closed	-$149K	–	9111
2023 Q3	$149K	Buy	+21,700	New	+$185K	﹤0.01%	7792
2023 Q2	–	Sell	-27,900	Closed	-$226K	–	8596
2023 Q1	$226K	Buy	+27,900	New	+$354K	﹤0.01%	7660
2021 Q3	–	Sell	-21,900	Closed	-$385K	–	9832
2021 Q2	$385K	Buy	+21,900	New	+$497K	﹤0.01%	7729

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jane Street's ACRS Position: Q1 2026 in Review

Jane Street sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 27,216 shares — an estimated $91.8K sold.

Jane Street first reported a position in ACRS in Q2 2019 and held it in 19 quarters. The position peaked at $1.57M in Q2 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

Jane Street reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
Jane Street sold 27,216 Aclaris Therapeutics shares in Q1 2026, an estimated $91.8K.
Jane Street first reported a position in Aclaris Therapeutics in Q2 2019 and held it in 19 quarters.
Jane Street's Aclaris Therapeutics position peaked at $1.57M in Q2 2023.
136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.